Originally published by our sister publication Pharmacy Practice News
PHOENIX—Pharmacists have many guideline-directed options for front-line treatment of metastatic renal cell carcinoma (mRCC). But the path forward becomes less clear in the second-line setting or beyond, speakers emphasized at the HOPA Annual Conference 2023.
The main challenge is the lack of data indicating which regimen is optimal for these subsequent rounds of therapy, noted Rowena (Moe) Schwartz,